Appendix 4E and 2019 Full Year Results
Key Developments Achieved for MagSense^® Imaging Technology

Imagion Biosystems has released its Appendix 4E and Preliminary Results for the Full Year ended 31 December 2019.

Highlights:

• Successful completion of a GLP-compliant toxicology study demonstrating the MagSenseTMimaging agent safety profile
• Received Breakthrough Device designation from the US FDA for MagSenseTM for the detectionand staging of HER2 breast cancer
• Demonstrated MagSenseTM targeted nanoparticles may have commercial utility with existing MRIscanners
• Executed cost management steps to preserve capital and focus resources on planning for firstclinical study; net operating cash outflow reduced to $4.2 million (down from $6.6 million)
• Cash receipts up to $559K with a further $2 million in non-dilutive cash from R&D tax credit in Q3
• Successful $3.6 million Renounceable Rights Issue in Q4, strengthening balance sheet andproviding funds for continued development of the MagSenseTM imaging agent
• Net loss after tax $3.5M, 60% improvement vs 2018 ($8.8M)
• Cash balance of $3.4M at 31 December 2019

Download Appendix 4E and Full Year Results.